Group 1 - The Fourth Plenary Session of the 20th Central Committee emphasized the importance of high-level technological self-reliance and innovation as a strategic task for national development [1][2] - The integration of technological self-reliance and the development of new productive forces is seen as a logical prerequisite and core engine for each other, highlighting the need for deep integration of technological and industrial innovation [2][4] - The session called for seizing opportunities from the new round of technological revolution and industrial transformation, enhancing the overall effectiveness of the national innovation system, and continuously fostering new productive forces [2][4] Group 2 - The session stressed the need for original innovation and tackling key core technologies, which are essential for industrial upgrading and defining new rules in international competition [4][5] - The integration of technological innovation and industrial innovation is crucial for achieving high-quality development, with recommendations for establishing a demand-driven technology development system [6] - The session highlighted the importance of advancing digital China construction and the role of technology in supporting the transformation and upgrading of industries [4][6]

根据流域水工程联合调度计划，科学安排水库蓄水次序。截至10月24日，长江流域58座控制性水库死水 位以上蓄水量达1081亿立方米，再破"千亿"大关，为枯水期补水及春耕生产提供了有效水安全保障。 蓄水工作坚持"预"字当先，提前谋划。在精准预报基础上，及时编制并批复三峡及上游控制性水库蓄水 计划。9月10日，三峡水库以较近5年同期偏高7.2米的水位启动蓄水，为完成年度任务赢得主动。 此外，有关部门充分利用数字孪生等技术成果，动态优化调度，有效应对华西秋雨。蓄水期间，成功拦 蓄9次较大洪水过程，削减洪峰，避免中下游干流超警与库区淹没，实现秋汛防御与蓄水目标双赢。 面对主汛期来水显著偏少、流域旱情严峻的挑战，水利部与长江水利委员会坚持旱涝同防同治，统筹防 洪、供水、发电、航运、生态等多目标，实施精准联合调度，最终实现汛后控制性水库基本蓄满，流域 水库群总蓄水量达1081亿立方米，创下历史新高。 在调度过程中，相关部门突出系统思维，科学优化水库运行。针对偏旱形势，三峡水库实施3次保灌溉 补水，累计补水72亿立方米，有效保障了沿江城市及中下游5558万亩农田灌溉；主汛期提前将水位消落 至152米左右，预留约38亿立方米抗 ...

Core Viewpoint - The innovative intracranial injection method for oncolytic virus therapy enhances the convenience of treating brain tumors, demonstrating safety and efficacy in treating pediatric diffuse intrinsic pontine glioma (DIPG) with the new oncolytic virus Ad-TD-nsIL12 [1][6] Group 1: Oncolytic Virus Therapy - Oncolytic virus therapy is emerging as a disruptive new strategy for cancer treatment, with the potential to revolutionize clinical practices [2] - This therapy selectively infects and destroys tumor cells while activating the immune system, providing a dual mechanism of action against tumors [3][4] - The engineered oncolytic virus is designed to replicate specifically within tumor cells, minimizing harm to normal cells and enhancing therapeutic efficacy [5] Group 2: Mechanism and Design - The oncolytic virus used in the study is based on human adenovirus type 5 (Ad5) and has undergone genetic modifications to improve targeting and reduce toxicity [5] - Key genetic deletions enhance the virus's ability to kill tumor cells and improve the presentation of tumor-specific antigens to the immune system [5] - The introduction of non-secretory interleukin-12 (IL-12) maintains normal levels in the bloodstream, promoting systemic anti-tumor immunity while avoiding side effects from elevated IL-12 levels [5] Group 3: Clinical Trials and Results - Clinical trials have confirmed the safety of the oncolytic virus Ad-TD-nsIL12, with significant preclinical and clinical evidence supporting its effectiveness [6] - Over 200 oncolytic virus-related clinical trials are currently underway globally, with a significant portion originating from China [7] - Notable results from CG Oncology's phase 3 trial showed complete tumor disappearance in 82 out of 110 patients treated with their oncolytic virus therapy [7] Group 4: Future Directions - To accelerate the clinical translation of oncolytic virus therapy, collaboration between basic and clinical research is essential, along with enhanced communication among researchers and clinicians [7] - Future studies will explore the combination of oncolytic virus therapy with surgery, radiotherapy, and antibody treatments to address the heterogeneity of malignant tumors [8]

Core Insights - A new method to effectively improve negative symptoms of schizophrenia has been discovered by Dr. Han Yuyi from Harbin First Specialized Hospital, with results published in the international journal "Brain Stimulation" [1][2] Group 1: Research Findings - Schizophrenia patients experience both positive symptoms (hallucinations, delusions) and negative symptoms (emotional flatness, social withdrawal), with the latter often overlooked [1] - Current drug treatments are effective for positive symptoms but show limited efficacy for negative symptoms [1] - Non-invasive neurostimulation techniques, such as transcranial magnetic stimulation, are being explored for treating negative symptoms, but existing methods have significant limitations [1] Group 2: Clinical Study - The study involved 80 schizophrenia patients primarily exhibiting negative symptoms, divided into a true stimulation group and a sham stimulation group [2] - The true stimulation group received individualized accelerated intermittent theta-burst stimulation for 10 days, with four sessions daily, each consisting of 1800 pulses [1][2] - Results showed a significant reduction in negative symptoms in the true stimulation group after four weeks, with a response rate of 77.5% compared to 17.5% in the sham group [2] Group 3: Effectiveness and Future Plans - The average score for negative symptoms in the true stimulation group decreased by 4.10 points, with an effect size of 0.83, indicating moderate to high treatment effectiveness [2] - Neuroactivity changes in the left middle temporal gyrus and weakened functional connectivity between the midbrain and middle temporal gyrus were associated with symptom improvement [2] - Future plans include larger multi-center clinical studies to optimize treatment parameters for broader patient access [2]

Core Viewpoint - The research team led by Professor Zhang Hongwei from Capital Medical University Sanbo Brain Hospital demonstrates the safety of oncolytic virus therapy and introduces an innovative "cystic channel" treatment approach to alleviate patient suffering and treatment burden [1] Group 1: Oncolytic Virus Therapy - Oncolytic virus therapy faces challenges as the immune system often eliminates the virus as a foreign entity, significantly shortening its effective attack period on tumors [1] - Clinical practice typically requires repeated administration to ensure therapeutic efficacy, which can be burdensome for patients [1] Group 2: Cystic Channel Treatment Approach - The traditional method of administering oncolytic virus therapy involves puncture injections into the brain, leading to additional brain damage and requiring separate surgical procedures for each injection [1] - The innovative "cystic channel" treatment allows for a single surgical procedure to place a small cyst under the patient's skin, connecting it to the tumor via a tube [1] - Subsequent administrations of the oncolytic virus can be done by injecting the drug into the cyst, which then delivers it directly to the tumor, minimizing repeated brain punctures and reducing the number of surgeries required, thus significantly alleviating the treatment burden on patients [1]

Core Insights - The article discusses the establishment of a comprehensive prevention and control model for hereditary rare diseases in Changsha, China, led by the reproductive and genetic team at the CITIC Xiyuan Reproductive and Genetic Specialist Hospital, which has been published in the international journal "Human Genetics and Genomics Advances" [1][2]. Group 1: Project Overview - The project, initiated in 2021, was commissioned by the Changsha Municipal Health Commission and involved collaboration with various local health institutions to implement a comprehensive health project for hereditary rare diseases [2]. - From January 2022 to June 2023, the project team conducted online family lineage surveys for 85,391 couples planning for pregnancy or in early pregnancy, and genetic testing for 1,414 high-risk couples [2]. - The results indicated that 562 couples were at high risk of having children with rare diseases, with a positive rate of 39.75% [2]. Group 2: Impact and Findings - The project successfully provided reproductive interventions for 319 families in Changsha, preventing the birth of 141 children with rare diseases [2]. - Genetic testing led to 25.09% of participating couples optimizing their reproductive decisions, and 32.74% of families altered their reproductive plans, significantly reducing the birth rate of children with rare diseases [2]. - The team discovered that "simultaneous testing of three family members" was a key factor in improving diagnostic rates, while individual testing could lead to missed diagnoses, providing critical insights for future testing strategies [2]. Group 3: Changsha Model - The project introduced the "Changsha Model" for the prevention and control of hereditary rare diseases, characterized by a government-led approach involving public participation, family lineage surveys, genetic testing, and reproductive interventions [3]. - This model aims for comprehensive coverage of reproductive populations starting from pre-marital and prenatal screenings, effectively identifying high-risk families and providing reproductive guidance to prevent intergenerational transmission of hereditary rare diseases [3]. - The findings indicate that this model is well-suited to China's context and addresses the gaps in diagnosis and management of hereditary rare diseases in resource-limited areas, contributing a "Chinese solution" to global rare disease prevention [3].

Core Viewpoint - The innovative intracranial injection method for oncolytic virus therapy enhances the treatment of brain tumors, demonstrating safety and efficacy in treating pediatric diffuse intrinsic pontine glioma (DIPG) [1][6]. Group 1: Oncolytic Virus Therapy - Oncolytic virus therapy is emerging as a disruptive new strategy for cancer treatment, with the potential to revolutionize clinical approaches [2]. - This therapy utilizes engineered viruses that selectively infect and destroy tumor cells while activating the immune system, providing a dual mechanism of action [3][4]. - The modified oncolytic virus (Ad-TD-nsIL12) shows improved targeting of tumor cells and reduced toxicity to normal cells through specific genetic alterations [5][6]. Group 2: Clinical Trials and Efficacy - Recent clinical trials have confirmed the safety of the oncolytic virus Ad-TD-nsIL12, with significant preclinical and clinical evidence supporting its effectiveness [6]. - Global statistics indicate over 200 ongoing clinical trials related to oncolytic viruses, with a substantial portion originating from China, highlighting the rapid advancement in this field [7]. - A notable study demonstrated that a new oncolytic virus (VG161) significantly extended the median overall survival of patients with recurrent liver cancer from 9.4 months to 17.3 months [7]. Group 3: Future Directions - The focus for future research includes enhancing collaboration between basic and clinical research to facilitate the transition of oncolytic virus therapies into clinical practice [7]. - The team plans to explore combination therapies involving oncolytic viruses with surgery, chemotherapy, and antibody treatments to address the heterogeneity of malignant tumors [8].

Core Insights - The article discusses the development of a "dandelion-like nanoprobe detection platform" by a research team led by Professor Zhang Yan from Qilu Normal University, aimed at addressing the challenges of sensitivity and specificity in tumor marker detection for early cancer screening [1] Group 1: Technology and Innovation - The dandelion-like nanoprobe detection platform is inspired by the seed dispersal mechanism of dandelions, providing an innovative solution for detecting trace molecules in life sciences [1] - The platform utilizes magnetic microparticles and gold nanoparticles, where the former carries specific DNA sequences to identify the "troublemaker" molecule FTO, and the latter is designed to release fluorescent signals upon detection [2][3] - The detection mechanism allows for the amplification of signals, enabling the identification of even minimal amounts of FTO, thus enhancing the sensitivity of cancer detection [3] Group 2: Clinical Applications - The ultimate goal of the research is to simplify early cancer screening to a level comparable to blood glucose testing, allowing for the detection of elevated FTO levels as potential early cancer signals [4] - The platform can be applied in various scenarios, including the detection of purified FTO, analysis of cell lysates, and tissue sample extracts, meeting diverse needs for inhibitor screening and clinical diagnosis [4] - By detecting FTO activity in blood, the platform aims to identify latent cancer cells and potentially use FTO inhibitors to restore the function of tumor suppressor genes, thereby inhibiting cancer cell proliferation [5]

研究团队将不同共振频率组合的纤毛集成于同一阵列，发现在钢琴曲和语音等声音信号的刺激下， 纤毛阵列的振动响应模式与声音信号时频图基本一致，显示出其在声音频率可视化解析方面的潜力。团 队进一步研究证实，共振状态下的纤毛可显著加快液体流速，可有效促进模型药物在液体环境中的释放 与扩散。 在此基础上，研究团队分别将胰岛素和胰高血糖素搭载于不同长度直径比的仿生纤毛上，构建了胶 囊型的声学共振响应性药物递释器件，并在1型糖尿病模型小鼠身上验证了药物递释器件双向调控血糖 的功能。 "通过施加不同频率的声波刺激，这一器件可选择性触发胰岛素或胰高血糖素的释放。"顾臻告诉记 者，未来，这一仿生人工纤毛阵列可以进一步优化其材料与结构设计，以拓宽频率响应范围，提升对复 杂声音信号的解析能力，用于执行更多个性化任务。 科技日报讯 （记者江耘）10月22日，记者从浙江大学获悉，该校药学院、金华研究院顾臻教授、 王金强研究员团队开发了一种仿生人工纤毛阵列，可通过声学共振机制实现对声音信号的可视化解析， 并利用可听频率声波实现共振响应性药物递释。相关研究日前发表于学术期刊《自然·生物医学工 程》。 人类感知声音的过程很精巧——耳蜗中的基底膜 ...

Core Insights - The launch of the "Gezhouba" vessel marks a significant advancement in China's inland shipping, transitioning to a "zero-emission, intelligent" development phase, setting a global benchmark for new energy vessels [1][2] Group 1: Vessel Specifications - The "Gezhouba" vessel measures 129.98 meters in length, 22 meters in width, and has a maximum load capacity of 13,740 tons [1] - It is equipped with 12 lithium battery boxes, providing an energy capacity of approximately 24,000 kilowatt-hours, enabling a range of up to 500 kilometers [1] Group 2: Technological Innovations - The vessel features an intelligent navigation control system with remote sailing capabilities, enhancing safety and operational efficiency [1] - It incorporates a submerged multi-stage cooling system and a fire extinguishing system using heptafluoropropane, along with a battery monitoring and fault diagnosis system for safety [1] Group 3: Environmental Impact - The operational estimates suggest that the vessel can replace approximately 617.5 tons of fuel annually, leading to a reduction of about 2,052 tons of carbon dioxide emissions [1] Group 4: Industry Significance - The vessel represents a breakthrough in integrating new energy power, intelligent control, and supporting infrastructure, validating key technologies such as large-capacity batteries and distributed DC power systems [2] - It provides critical technological support and an innovative model for the high-quality development of Yangtze River shipping under the strategy of ecological protection [2]